PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78

Chiharu Moriya1 | Hiroaki Taniguchi1 | Satoru Nagatoishi2,3 | Hisayoshi Igarashi1 | Kouhei Tsumoto2,4,5 | Kohzoh Imai6

1Center for Antibody and Vaccine Therapy, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
2Department of Bioengineering, School of Engineering, The University of Tokyo, Tokyo, Japan
3Project Division of Advanced Biopharmaceutical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
4Drug Discovery Initiative, The University of Tokyo, Tokyo, Japan
5Laboratory of Medical Proteomics, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
6The Institute of Medical Science, The University of Tokyo, Tokyo, Japan

Correspondence
Hiroaki Taniguchi, Center for Antibody and Vaccine Therapy, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Email: h-tani@ims.u-tokyo.ac.jp

Present address
Hisayoshi Igarashi, Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.

Funding information
Ministry of Education, Culture, Sports, Science and Technology (Grant/Award Number: "KAKENHI Grant Number JP16H04710").

PRDM14 is overexpressed in various cancers and can regulate cancer phenotype under certain conditions. Inhibiting PRDM14 expression in breast and pancreatic cancers has been reported to reduce cancer stem-like phenotypes, which are associated with aggressive tumor properties. Therefore, PRDM14 is considered a promising target for cancer therapy. To develop a pharmaceutical treatment, the mechanism and interacting partners of PRDM14 need to be clarified. Here, we identified the proteins interacting with PRDM14 in triple-negative breast cancer (TNBC) cells, which do not express the three most common types of receptor (estrogen receptors, progesterone receptors, and HER2). We obtained 13 candidates that were pulled down with PRDM14 in TNBC HCC1937 cells and identified them by mass spectrometry. Two candidates—glucose-regulated protein 78 (GRP78) and heat shock protein 90-α (HSP90α)—were confirmed in immunoprecipitation assay in two TNBC cell lines (HCC1937 and MDA-MB231). Surface plasmon resonance analysis using GST-PRDM14 showed that these two proteins directly interacted with PRDM14 and that the interactions required the C-terminal region of PRDM14, which includes zinc finger motifs. We also confirmed the interactions in living cells by NanoLuc luciferase-based bioluminescence resonance energy transfer (NanoBRET) assay. Moreover, HSP90 inhibitors (17DMAG and HSP990) significantly decreased breast cancer stem-like CD24−CD44+ and side population (SP) cells in HCC1937 cells, but not in PRDM14 knockdown HCC1937 cells. The combination of the GRP78 inhibitor HA15 and PRDM14 knockdown significantly decreased cell proliferation and SP cell number in HCC1937 cells. These results suggest that HSP90α and GRP78 interact with PRDM14 and participate in cancer regulation.

KEYWORDS
GRP78, heat shock protein, HSP90α, PRDM14, protein-protein interaction

INTRODUCTION

PRDM14 is a member of the PR domain-containing family. It is specifically expressed in ES cells and primordial germ cells and has multiple functions, including a scaffold for chromatin remodeling. a
transcription regulator required for maintaining pluripotency, and a required component for epigenetic reprogramming. PRDM14 overexpression in several cancers has been shown to be related to cancer properties such as proliferation, drug resistance, and differentiation. We have previously reported that knockdown of PRDM14 expression decreased cancer stem-like phenotypes, which are considered responsible for cancer initiation and progression in breast and pancreatic cancer cells. Because siRNA-based therapy targeting PRDM14 by tail vein injection decreased xenograft tumor and metastasis in mice, PRDM14 is considered a promising target for the treatment of these cancers. However, the working mechanism of PRDM14 in cancers is mostly unknown.

PRDM14 consists of a PR domain and six C2H2-type zinc finger motifs. The PR domain is related in sequence to a SET methyltransferase domain but histone methyltransferase activity is found in only a subset of the PRDM family. Although PRDM14 indirectly associates with a methyltransferase process by recruiting a partner, innate methyltransferase activity has not been detected in PRDM14. The zinc finger motif is a DNA-binding entity and, in some cases, also interacts with RNA, protein, and lipid. PRDM14 was reported to interact with proteins by IP and/or pull-down, including components of PRC2 and KLF2 in ES cells, and TET enzymes in epiblast-like cells. These interactions regulate pluripotency, differentiation, and reprogramming. However, binding partners of PRDM14 were not identified in cancer cells.

Breast cancer is one of the most common cancers worldwide. Breast cancers that express one or more of the three most common types of receptor (estrogen receptors, progesterone receptors, and HER2) can be treated with hormone and/or trastuzumab therapies to achieve a good prognosis. However, TNBC, which lack all three types of receptor, are often more aggressive with poor prognosis and are more difficult to treat. We have reported that inhibition of PRDM14 decreased s.c. xenografted tumor growth and metastasis of TNBC cell lines, suggesting that PRDM14 is a good target for treating TNBC in patients. Elucidation of the binding partners of PRDM14 will help elucidate the mechanism whereby PRDM14 regulates cancer phenotypes, which could contribute to the development of a less costly treatment for patients with these cancers.

Heat shock proteins are highly conserved and are induced in response to several stimuli including environmental stress. HSPs are multifunctional; they possess chaperone activity, inhibit apoptosis by associating with factors of the apoptotic machinery, and contribute to cell survival by regulating the stability or degradation of selected proteins. In cancer cells, HSPs are highly expressed and further increased after stimulation. Moreover, HSP expression correlates with tumor growth, metastasis, and chemotherapy resistance. Thus, HSPs are an emerging target for cancer treatment. HSP90s is the most prominent member of the HSP90 family and many client proteins have been identified. The client proteins cover various cellular processes and include cancer-associated proteins, such as tumor suppressor proteins and mediators of invasion, metastasis, and angiogenesis. GRP78 is also known as BiP and belongs to the HSP70 family. Its expression is known to increase during ER stress, which takes place when unfolded and/or misfolded proteins accumulate in the ER lumen. GRP78 works as a protein chaperone to mitigate potential damage from the unfolded species.

In cancer cells, ER stress from microenvironmental factors, such as hypoxia and acidosis, upregulates GRP78 expression. In breast cancer, overexpressed GRP78 inhibits cell death by elevating anti-apoptotic proteins and promotes autophagy, which enhances survival and drug resistance.

To elucidate the molecular mechanism of PRDM14 in cancer cells, we carried out Halo pull-down from Halo-PRDM14 transduced TNBC HCC1937 cells, followed by mass spectrometry to identify binding partners. For the binding candidate proteins, we provided SPR analysis supporting that PRDM14 directly bound with HSP90α and GRP78. Furthermore, we carried out a NanoBRET binding assay to assess protein-protein interactions in living cells, which can be made available for screening of binding inhibitors in the future. Moreover, we carried out experiments using HSP90 and GRP78 inhibitors to assess their effects on PRDM14-mediated cell processes.

2 MATERIALS AND METHODS

2.1 Cell culture

The 293T cell line was purchased from ATCC (Manassas, VA, USA). The cell was identified by the cell banks using short tandem repeat analysis. The cells were cultured in DMEM (Thermo Fisher Scientific, San Jose, CA, USA) containing 10% FBS (GE Healthcare, Uppsala, Sweden). Two TNBC cell lines, HCC1937 and MDA-MB-231 cells, were obtained and cultured as described previously. All cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO2.

2.2 Plasmid construction

A DNA fragment encoding PRDM14-ΔC (amino acids 1-412) was inserted into pReceiver-Lv110 vector (GeneCopoeia, Rockville, MD, USA) to produce the plasmid encoding Halo-PRDM14-ΔC. For production of proteins tagged with NLuc at either the N- or C-terminus, a DNA fragment containing the ORF sequence was inserted into pFN31K or pFC32K NLuc CMV-neo Flexi vector (Promega, Madison, WI, USA) at the SflI and Pmel sites, respectively. The insert sequences of HSP90α and GRP78 are the same as those of FHC25301 and FHC10475, respectively (Kazusa DNA Res. Inst., Chiba, Japan).

2.3 Lentiviral transduction

The plasmid vectors used were HaloTag fusion human PRDM14 (Halo-PRDM14; EX-W1089-Lv110; GeneCopoeia), and HaloTag fusion EGFP (Halo-con; EX-EGFP-Lv110; GeneCopoeia). HCC1937
and MDA-MB231 cells were transduced using the Lenti-pack HIV Expression Packaging Kit (GeneCopoeia). shRNA-transduced HCC1937 cells (control shRNA and two anti-human PRDM14 shRNAs [sh#1 and sh#3]) were prepared as previously described.

2.4 | HaloTag pull-down and mass spectrometry

The HaloTag pull-down assay was carried out using HaloTag Mammalian Pull-Down System (Promega) according to the manufacturer’s instructions. Briefly, Halo-PRDM14 or Halo-con transduced HCC1937 and MDA-MB231 cells were collected, washed, and lysed. Equilibrated HaloLink Resin was mixed with the lysate, incubated, washed, and eluted with SDS elution buffer. The eluted samples were analyzed by SDS-PAGE and detected by silver stain (Invitrogen, Carlsbad, CA, USA). We selected bands that were present in both cell lines expressing Halo-PRDM14. The selected bands were excised and digested in-gel with trypsin. Peptides were extracted and analyzed by mass spectrometry. Proteins present in HCC1937 expressing Halo-con samples were excluded from further consideration.

2.5 | Immunoprecipitation

Immunoprecipitation was carried out using HCC1937 and MDA-MB231 cells expressing Halo fusion proteins. The cell lysates were incubated with each antibody and then TrueBlot anti-rabbit IgG beads (Rockland, Limerick, PA, USA) were added. After incubation, the binding proteins were eluted from the beads with 1x SDS Sample Buffer (62.5 mmol/L Tris pH 6.8, 2% SDS, 10% glycerol, 0.1 mol/L DTT, 0.005% bromophenol blue, 2% 2-mercaptoethanol). The following antibodies were used for IP: HSP90α (ab2928), and GRP78 (ab21685) from Abcam Inc. (Cambridge, MA, USA), and γ-catenin (#2309) from Cell Signaling Technology Inc. (Beverly, MA, USA).

2.6 | Protein analysis by automated capillary electrophoresis and immunodetection

Protein levels were quantified using an automated capillary electrophoresis and immunoassay system, Wes (ProteinSimple, Santa Clara, CA, USA) or western blotting as described previously. We used the following primary antibodies: PRDM14 (ab187881), HSP90α (ab2928), GRP78 (ab21685), and caspase-14 (ab174847) from Abcam Inc., GAPDH (#5174) and γ-catenin (#2309) from Cell Signaling Technology Inc., and Halo (G928A) from Promega. Secondary antibody used was TrueBlot HRP-conjugated anti-rabbit antibody (Rockland) for immunoprecipitated samples.

2.7 | NanoLuc fusion protein detection

NanoLuc fusion proteins were analyzed by luciferase activity. The lysates of NLuc fusion protein-transfected 293T were separated by non-reducing SDS-PAGE and transferred to PVDF membrane. The transferred membrane was treated with the substrate for NLuc and luminescence was detected with an ImageQuant Las-4010 system (GE Healthcare).

2.8 | Proteins

We used the following proteins for SPR analysis: Human PRDM14 (H00063978-P01, GST-Tag at N-terminus; Abnova Inc., Taipei, Taiwan), Human PRDM14 (AC; ab196396, GST-Tag at N-terminus; Abcam Inc.), Human Hsp90 alpha (ab48801, His-Tag; Abcam Inc.), Human GRP78 (SPR-107, His-Tag; Stress Marq Biosciences Inc., Victoria, BC, Canada), Human caspase-14 (BML-SE417; Enzo Life Sciences, Inc., Farmingdale, NY, USA), and Human γ-catenin (TP304209, MYC/DDK-Tag; OriGene Technologies, Inc., Rockville, MD, USA).

2.9 | Surface plasmon resonance analysis

Interactions between putative partner proteins and PRDM14 were investigated by SPR analysis using a Biacore X100 plus instrument (GE Healthcare). Anti-GST antibody was immobilized to the surface of a CM5 sensor chip with the GST capture kit (GE Healthcare) according to the manufacturer’s instructions. GST or GST-PRDM14 (ligand) was bound to the immobilized GST antibody on the CM5 sensor chip, and the analytes were flowed over the chip. HEPES-Buffered Saline-EP + buffer (10 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 3 mmol/L EDTA, 0.05% surfactant P20; GE Healthcare) was used as the running buffer. The sensor chip surface was regenerated with regeneration solution (10 mmol/L glycine-HCl, pH 2.1; GE Healthcare). Specific protein-protein interactions were identified by binding analysis of the initial screening and the association between recombinant proteins was examined with different concentrations of analyte by single-cycle kinetic analysis. The data were globally fit to a 1:1 interaction model to determine dissociation constant (K_D) for the interactions using BIA evaluation software Version 2.0.1 (GE Healthcare). Measurements were carried out at 25°C.

2.10 | NanoLuc luciferase-based bioluminescence resonance energy transfer

We carried out NanoBRET assays using a NanoBRET Nano-Glo detection System (Promega) according to the manufacturer’s instructions. Briefly, 293T cells were co-transfected with HaloTag and NLuc fusions using FuGENE reagent (Promega) according to the manufacturer’s instructions. The transfected cells were trypsinized, washed with PBS, resuspended in assay medium (Opti-MEM I Reduced Serum Medium, no phenol red [Thermo Fisher Scientific] + 4% FBS), re-plated to a 96-well plate, and incubated with HaloTag NanoBRET 618 Ligand (100 nmol/L final concentration) or DMSO as negative control for greater than 4 hours. NanoBRET Nano-Glo Substrate was added and donor emission (460 nm) and acceptor emission (618 nm) were measured using the GloMax Discover System (Promega). Raw NanoBRET ratio values with milliBRET units (mBU) were
calculated as $\text{RawBRET} = 618 \text{ nm Em/460 nm Em} \times 1000$. Corrected NanoBRET ratio values with milliBRET units were calculated as corrected BRET = RawBRET of experimental sample – RawBRET of negative control sample, which reflected energy transfer from a bioluminescent protein donor to a fluorescent protein acceptor as a result of protein-protein interactions.

For the initial screening, we carried out the NanoBRET assay with Halo-PRDM14 and the proteins tagged with NLuc at either N- or C-terminus and chose the combination that yielded a larger BRET ratio. To validate a NanoBRET assay without known inhibitors, we ascertained assay specificity by carrying out a simplified donor saturation assay. 1:1, 1:10, 1:100, and 1:1000 dilutions of NLuc relative to HaloTag DNA were used. If the protein-protein interactions were real, the donor saturation assay curve would reach an asymptote, whereas a negative control would not.

### 2.11 Inhibitors

DMAG-17, HSP990, VER155008, and HA15 were purchased from Selleck Chemicals (Houston, TX, USA). Cells were incubated for 24 hours, and then washed with inhibitors for 24 hours. DMSO was used as a solvent and the negative control for these experiments. The proliferation assay was carried out using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan). Isolation of SP cells and cell surface marker analyses were carried out using a FACSaria or FACSVerse flow cytometer (BD Biosciences, San Jose, CA, USA), as previously described.9

### 2.12 siRNA transfection

Two DNA-chimeric siRNAs targeting the coding region of PRDM14 (PRDM14_1082-1104 and PRDM14_1504-1526; si#2 and si#3, respectively) as well as a negative control DNA-chimeric siRNA (siNEGA) were purchased from RNAi Inc. (Tokyo, Japan).9 Cells were transfected with them using the Lipofectamine RNAiMAX Reagent (Thermo Fisher Scientific).

### 3 RESULTS

#### 3.1 Identification of proteins interacting with PRDM14 in TNBC cells

To identify intracellular protein partners of PRDM14 in TNBC cells, we carried out Halo pull-down assays followed by mass spectrometry. The eluted samples from Halo pull-down assays of HaloTag protein-transduced MDA-MB231 and HCC1937 cells were analyzed by SDS-PAGE (Figure 1). The 4 selected bands in Halo-PRDM14-transduced HCC1937 cells were analyzed by mass spectrometry and 13 proteins were identified as potential binding partners of PRDM14 (Table 1). The candidates included a variety of proteins including four heat shock proteins (HSP90α, GRP78, HSC70, and HSPA1L), 3 proteins of the desmosome (Desmoglein 1, Desmoplakin isoform 1, and Dsc1a), a member of Armadillo family γ-Catenin, which is involved in Wnt signaling, and Hornerin, which is aberrantly expressed and functional in breast cancer.

Halo pull-down samples from HCC1937 and MDA-MB231 cells were additionally analyzed by immunodetection. HSP90α, GRP78, and γ-Catenin were detected, but Caspase-14 was not (Figure 2A). Subsequently, we carried out an immunoprecipitation assay using antibodies for HSP90α, GRP78, or γ-Catenin on Halo-PRDM14 transduced HCC1937 and MDA-MB231 cell lysates (Figure 2B). Halo-PRDM14 was detected in all 3 immunoprecipitated samples from both cell lines (Figure 2C). Interactions of Halo-con and the proteins were not observed in either the Halo pull-down or the immunoprecipitation assays (Figure S1). These results suggest that HSP90α, GRP78, and γ-Catenin interacted with PRDM14 in TNBC cells.

#### 3.2 Confirmation of direct interactions between PRDM14 and selected proteins by SPR analysis

To determine whether interactions between PRDM14 and the identified proteins were direct or indirect, we carried out SPR experiments using a Biacore instrument. GST-PRDM14 protein was captured by an anti-GST antibody-immobilized sensor chip, which was used as bait for the candidate proteins. Stable binding of GRP78, HSP90α, and γ-Catenin to GST-PRDM14 was detected (Figure 3A). Stable binding between PRDM14 and Caspase-14 was not detected (Figure 3A), which agrees with the immunodetection data from Halo pull-down samples (Figure 2A). Next, we carried out kinetic analysis using data from different concentrations of the two heat shock proteins (GRP78 and HSP90α) to assess the equilibrium dissociation constant ($K_D$) values (Figure 3B). $K_D$ values of GRP78 and HSP90α with PRDM14 were $3.28 \times 10^{-8}$ and $5.59 \times 10^{-7}$ mol/L, respectively.
suggesting they directly bind with relatively high affinity. To identify the region of PRDM14 that binds to the proteins, we carried out kinetic analysis with GST-PRDM14-ΔC protein, which lacks the C-terminal region including the zinc finger motifs (Figure 3C). Interactions between the chaperone proteins and PRDM14-ΔC were not detected (Figure 3D). We confirmed that PRDM14-ΔC protein bound other proteins by SPR analysis (Figure S2). These results indicate that PRDM14 binds directly to GRP78 and HSP90α, and the binding requires the C-terminus of PRDM14.

### 3.3 Interactions between PRDM14 and selected proteins assessed by intracellular NanoBRET analysis

To validate the protein-protein interaction of PRDM14 with HSP90α and GRP78 in vivo, we carried out NanoBRET analysis (Figure 4A). The NanoBRET assay uses an NLuc fusion protein as an energy donor and a fluorescently labeled HaloTag fusion protein as the energy acceptor. The optimized blue-shifted NLuc donor paired with the red-shifted HaloTag acceptor minimizes spectral overlap within

---

**TABLE 1** Binding partners of PRDM14 identified by mass spectrometry

| Description                              | Score | Coverage | # Peptides | # PSM |
|------------------------------------------|-------|----------|------------|-------|
| Heat shock protein HSP 90-alpha, HSP90α | 11.30 | 6.15     | 3          | 4     |
| Glucose-regulated protein, GRP78         | 118.99| 30.67    | 19         | 47    |
| Heat shock cognate 71 kDa protein, HSC70 | 141.06| 27.09    | 17         | 55    |
| Heat shock 70 kDa protein 1-like, HSPA1L | 85.99 | 22.66    | 14         | 32    |
| Desmoglein-1                             | 34.39 | 7.91     | 7          | 15    |
| Desmoplakin isoform I                    | 54.96 | 6.13     | 20         | 29    |
| Dscl1 precursor                          | 7.48  | 2.77     | 2          | 4     |
| γ-Catenin                                | 17.41 | 9.81     | 7          | 10    |
| Hornerin                                 | 26.70 | 3.25     | 1          | 9     |
| Caspase-14                                | 11.80 | 13.22    | 3          | 5     |
| Dermcidin                                | 9.19  | 20.00    | 2          | 3     |
| Serpin Family B Member 12, SERPINB12     | 6.95  | 9.29     | 2          | 3     |
| Profilagrin                              | 6.19  | 3.21     | 2          | 3     |

Coverage: The percentage of the protein sequence covered by identified peptides.

# Peptides, total number of distinct peptide sequences identified in the protein group.

# PSM, number of peptide spectrum matches. Number of PSM is the total number of identified peptide spectra matched for the protein. The PSM value may be higher than the number of peptides identified for high-scoring proteins because peptides may be identified repeatedly.

HSP, heat shock protein.
the assay. 293T cells were co-transfected with Halo-PRDM14 and NLuc fusion HSP90α or GRP78 (tagged with NLuc at either the N- or C-terminus) (Figure 4B). We chose HSP90α-NLuc and NLuc-GRP78 because they yielded a larger BRET ratio than the opposite configurations in preliminary experiments with Halo-PRDM14 (Figure S3A). The donor saturation assay curves of HSP90α-NLuc and NLuc-GRP78 with Halo-PRDM14 reached saturation (Figure 4C). The curves with Halo-PRDM14-DCC and Halo-con did not reach saturation (Figures 4D and S3B,C). These results also indicate the interactions of PRDM14 with HSP90α and GRP78 require the C-terminal region of PRDM14 in living cells.

To determine whether PRDM14 expression is regulated by the molecular chaperones GRP78 and HSP90α, two TNBC cell lines were transfected with HSP90α-NLuc or NLuc-GRP78, or Halo-PRDM14 reached saturation (Figure 4C). The curves with Halo-PRDM14-DCC and Halo-con did not reach saturation (Figures 4D and S3B,C). These results also indicate the interactions of PRDM14 with HSP90α and GRP78 require the C-terminal region of PRDM14 in living cells.

To determine whether PRDM14 expression is regulated by the molecular chaperones GRP78 and HSP90α, two TNBC cell lines were transfected with HSP90α-NLuc or NLuc-GRP78, or Halo-PRDM14 alone. PRDM14 expression was not increased by the transfection of HSP90α or GRP78 (Figure S3D). In addition, Halo-PRDM14 induction had no impact on the expression of HSP90α or GRP78 (Figure S3E). These results suggest that the examined binding partners do not affect each other’s expression.

3.4 Effect of inhibitors on HSP90α and GRP78

To determine the physiological relevance of the interactions between PRDM14 and HSP90α or GRP78, we used HSP90 and GRP78 inhibitors. HCC1937 and MDA-MB231 cells were treated with 2 HSP90 inhibitors, 17DMAG (3 μmol/L) and HSP90α (1 μmol/L), an HSP70 family (HSP70, HSC70, and GRP78) inhibitor, VER155008 (100 μmol/L), and a GRP78 inhibitor, HA15 (100 μmol/L). PRDM14 expression was not changed by the inhibitors (Figure S4A). Proliferation of HCC1937 cells was significantly decreased by the inhibitors (P < .05) (Figure 5A). Combination of HA15 and PRDM14 knockdown reduced proliferation in both shPRDM14-transduced HCC1937 cells (sh#1 and sh#3) as compared with that in control shRNA-transduced cells (P < .01) (Figure 5B). Decreased proliferation in HA15-treated, PRDM14 knockdown cells was also confirmed in DNA-chimeric siRNA-transfected HCC1937 and MDA-MB231 cells (P < .05) (Figure S4B). Next, we assessed the effects of the inhibitors on the numbers of breast cancer stem-like CD24−CD44+ and SP cells. In HCC1937 cells, two HSP90 inhibitors

FIGURE 3 Binding and affinity analysis by surface plasmon resonance. A, Sensorgrams of the proteins (10 μg/mL) binding to surface GST-PRDM14. B, Different concentrations of HSP90α and glucose-regulated protein 78 (GRP78) (Conc 1-5) flowed over GST-PRDM14 on the anti-GST-immobilized sensor chip and analyzed by single-cycle kinetic analysis. The donor saturation assay curves of HSP90α-NLuc and NLuc-GRP78 with Halo-PRDM14 reached saturation (Figure 4C). The curves with Halo-PRDM14-DCC and Halo-con did not reach saturation (Figures 4D and S3B,C). These results also indicate the interactions of PRDM14 with HSP90α and GRP78 require the C-terminal region of PRDM14 in living cells.

To determine whether PRDM14 expression is regulated by the molecular chaperones GRP78 and HSP90α, two TNBC cell lines were transfected with HSP90α-NLuc or NLuc-GRP78, or Halo-PRDM14 alone. PRDM14 expression was not increased by the transfection of HSP90α or GRP78 (Figure S3D). In addition, Halo-PRDM14 induction had no impact on the expression of HSP90α or GRP78 (Figure S3E). These results suggest that the examined binding partners do not affect each other’s expression.
significantly decreased the number of CD24⁺/CD44⁺ cells \((P < .0001)\) (Figure 5C), whereas VER155008 and HA15 did not (Figure S4C). Aside from VER155008, all inhibitors decreased the proportion of SP cells in HCC1937 cells \((P < .01)\) (Figure 5D). The inhibitors did not decrease the number of CD24⁺/CD44⁺ and SP cells in MDA-MB231 (Figure S4D,E). Subsequently, shRNA-transduced HCC1937 cells were treated with the inhibitors. The number of CD24⁺/CD44⁺ cells in shPRDM14 was significantly reduced as compared with that in sh control cells \((P < .001)\) (Figure 5E), as previously reported.\(^{10}\) The inhibitors did not significantly change cell population in shPRDM14 cells (Figure 5E). The number of SP cells in shPRDM14 was significantly reduced as compared with that in sh control cells \((P < .001)\) (Figure 5F) as we have previously reported.\(^{10}\) HSP90 inhibitors did not change the number of SP cells, whereas the GRP78 inhibitor HA15 significantly decreased SP cell number in shPRDM14 as compared with that of the control \((P < .05)\) (Figure 5F).

4 | DISCUSSION

PRDM14 is overexpressed and regulates cancer properties in some cancers including TNBC, which is aggressive and difficult to treat. Because silencing PRDM14 expression in the cancers decreases cancer stem-like phenotypes including tumor formation and metastasis,\(^{9,10}\) PRDM14 is considered a promising target for cancer therapy. Identifying the binding partners of PRDM14 in cancers may contribute to the development of inhibitors targeting the PRDM14 working mechanism. We identified HSP90α and GRP78 as direct binding partners of PRDM14 in TNBC cells, whereas the binding patterns of PRDM14 with the other candidates are still under investigation.

Our data show that PRDM14 directly interacts with two heat shock proteins, GRP78 and HSP90α, and the interactions require the C-terminal region including the zinc finger motifs, which can interact with DNA, RNA, protein, and lipid. Many reports have shown that overexpression of other C2H2 zinc finger-containing proteins is related to several processes such as cell proliferation, invasion, migration, and drug resistance resulting in tumor progression for various cancers.\(^{37-40}\) Moreover, a relationship between zinc finger proteins and the heat shock response has been reported;\(^{41,42}\) a zinc finger protein ZC3H11 binds to mRNAs encoding heat-shock protein homologues and is required for stabilization of them after heat shock in *Trypanosoma brucei*.\(^{42}\) Although we observed that PRDM14 induced by transfection did not change the expression of HSP90α or GRP78 (and vice versa) in two TNBC cell lines (Figure S3D,E), PRDM14 may have roles within the heat shock response. The effects of zinc finger motifs on the function of PRDM14 should also be examined.

Heat shock proteins including HSP90α and GRP78 are highly expressed in cancer cells and are further increased after various stimuli. Moreover, they are considered targets in cancer treatment because their expressions are associated with cancer properties such as tumor growth, metastasis, and chemotherapy resistance. HSP inhibitors are emerging as a strategy for cancer treatment, and various
|     | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|--------|--------|------------|------|
| 0%  |        |        |            |      |
| 50% |        |        |            |      |
| 100%|        |        |            |      |

**Relative cell viability**

|     | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|--------|--------|------------|------|
| 0%  |        |        |            |      |
| 50% |        |        |            |      |
| 100%|        |        |            |      |

**Relative cell viability**

|     | DMSO | 17DMAG | HSP990 |
|-----|------|--------|--------|
| CD44|      |        |        |

**CD44**

|     | DMSO | 17DMAG | HSP990 |
|-----|------|--------|--------|
| CD24|      |        |        |

**CD24**

|     | DMSO | 17DMAG | HSP990 |
|-----|------|--------|--------|
| SP cells (%) |      |        |        |

**SP cells (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| CD24-CD44+ (%) |      |        |        |            |      |

**CD24-CD44+ (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| SH con |      |        |        |            |      |
| sh#1  |      |        |        |            |      |
| sh#3  |      |        |        |            |      |

**SH con**

|     | DMSO | 17DMAG | HSP990 |
|-----|------|--------|--------|
| CD44 |      |        |        |

**CD44**

|     | DMSO | 17DMAG | HSP990 |
|-----|------|--------|--------|
| CD24 |      |        |        |

**CD24**

|     | DMSO | 17DMAG | HSP990 | HA15 |
|-----|------|--------|--------|------|
| SP cells (%) |      |        |        |      |

**SP cells (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| CD24-CD44+ (%) |      |        |        |            |      |

**CD24-CD44+ (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| SH con |      |        |        |            |      |
| sh#1  |      |        |        |            |      |
| sh#3  |      |        |        |            |      |

**SH con**

|     | DMSO | 17DMAG | HSP990 | HA15 |
|-----|------|--------|--------|------|
| CD44 |      |        |        |      |

**CD44**

|     | DMSO | 17DMAG | HSP990 | HA15 |
|-----|------|--------|--------|------|
| CD24 |      |        |        |      |

**CD24**

|     | DMSO | 17DMAG | HSP990 | HA15 |
|-----|------|--------|--------|------|
| SP cells (%) |      |        |        |      |

**SP cells (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| CD24-CD44+ (%) |      |        |        |            |      |

**CD24-CD44+ (%)**

|     | DMSO | 17DMAG | HSP990 | VER155008 | HA15 |
|-----|------|--------|--------|------------|------|
| SH con |      |        |        |            |      |
| sh#1  |      |        |        |            |      |
| sh#3  |      |        |        |            |      |

**SH con**
FIGURE 5  Effects of HSP90 and GRP78 inhibitors. A, Proliferation assay with HSP90 inhibitors (17DMAG and HSP990), an HSP70 family inhibitor (VER155008), and a GRP78 inhibitor (HA15) using HCC1937 cells. B, Proliferation assay with the inhibitors using shRNA-transduced HCC1937 cells. C, Expression of CD24 and CD44 in HSP90 inhibitor-treated HCC1937 cells was analyzed by flow cytometry. D, Side population (SP) cells in inhibitor-treated HCC1937 cells were analyzed by flow cytometry using Hoechst 33342 dye. Reserpine, a multi-drug transporter inhibitor, was used as a control for SP. E, Expression of CD24 and CD44 in HSP90 inhibitor-treated, shRNA-transduced HCC1937 cells was analyzed by flow cytometry. F, SP cells in inhibitor-treated, shRNA-transduced HCC1937 cells analyzed by flow cytometry using Hoechst 33342 dye. Data are shown as mean ± SD. ****P < .0001, ***P < .001, **P < .01, *P < .05. GRP78, glucose-regulated protein 78; HSP, heat shock protein; ns, not significant.
REFERENCES

1. Hohenauer T, Moore AW. The Prdm family: expanding roles in stem cells and development. Development. 2012;139:2267-2282.

2. Tsuneyoshi N, Sumi T, Onda H, Nogima H, Nakatsuji N, Suemori H. PRDM14 suppresses expression of differentiation marker genes in human embryonic stem cells. Biochem Biophys Res Commun. 2008;367:899-905.

3. Payer B, Rosenberg M, Yamaji M, et al. Tsix RNA and the germline factor, PRDM14, link X reactivation and stem cell reprogramming. Mol Cell. 2013;52:805-818.

4. Yamaji M, Ueda J, Hayashi K, et al. PRDM14 ensures naive pluripotency through dual regulation of signaling and epigenetic pathways in mouse embryonic stem cells. Cell Stem Cell. 2013;12:368-382.

5. Yamaji M, Seki Y, Kurimoto K, et al. Critical function of Prdm14 for the establishment of the germ cell lineage in mice. Nat Genet. 2008;40:1016-1022.

6. Nishikawa N, Toyota M, Suzuki H, et al. Gene amplification and overexpression of PRDM14 in breast cancers. Cancer Res. 2007;67:9649-9657.

7. Bi HK, Shi HB, Zhang T, Cui G. PRDM14 promotes the migration of human non-small cell lung cancer through extracellular matrix degradation in vitro. Chin Med J (Engl). 2015;128:373-377.

8. Zhang T, Meng L, Dong W, et al. High expression of PRDM14 correlates with cell differentiation and is a novel prognostic marker in resected non-small cell lung cancer. Med Oncol. 2013;30:605.

9. Moriya C, Taniguchi H, Miyata K, Nishiyama N, Kataoka K, Imai K. Inhibition of PRDM14 expression in pancreatic cancer suppresses cancer stem-like properties and liver metastasis in mice. Carcinogenesis. 2017;38:638-648.

10. Taniguchi H, Hoshino D, Moriya C, et al. Silencing PRDM14 expression by an innovative RNAi therapy inhibits stemness, tumorigenicity, and metastasis of breast cancer. Oncotarget. 2017;8:46856-46874.

11. Mzouighi S, Tan YX, Low D, Guccione E. The role of PRDMs in cancer: one family, two sides. Curr Opin Genet Dev. 2016;36:83-91.

12. Wolfe SA, Nekludova L, Pabo CO. DNA recognition by Cys2His2 zinc finger domains. Methods Mol Biol. 2010;649:479-491.

13. Konieczny P, Stepniak-Konieczna E, Sobczak K. MBNL proteins and their target RNAs, interaction and splicing regulation. Nucleic Acids Res. 2014;42:10873-10887.

14. Brayer KJ, Kulshreshtha S, Segal DJ. The protein-binding potential of C2H2 zinc finger domains. Cell Biochem Biophys. 2008;51:9-19.

15. Gaulleir JM, Simonsen A, D’Arrigo A, Bremnes B, Stenmark H, Aasland R. FYVE fingers bind PtdIns(3)P. Nature. 1998;394:432-433.

16. Matthews JM, Sunde M. Zinc fingers—folds for many occasions. IUBMB Life. 2002;54:351-355.

17. Okashta N, Suwa Y, Nishimura O, et al. PRDM14 drives OCT3/4 recruitment via active demethylation in the transition from primed to naive pluripotency. Stem Cell Reports. 2016;7:1072-1086.

18. Chan YS, Goke J, Lu X, et al. A PRC2-dependent repressive role of PRDM14 in human embryonic stem cells and induced pluripotent stem cell reprogramming. Stem Cells. 2013;31:682-692.

19. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl 6):vi7-v12.

20. Young JC, Agashe VR, Siegers K, Hartl FU. Pathways of chaperone-mediated protein folding in the cytosol. Nat Rev Mol Cell Biol. 2004;5:781-791.

21. Fu Y, Li J, Lee AS. GRP78/BIP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. Cancer Res. 2007;67:3734-3740.

22. Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C. Apoptosis versus cell differentiation: role of heat shock proteins HSP90, HSP70 and HSP27. PLoS Pathog. 2009;5:1003286.

23. Zhang YH, Zhang Y, Li M, et al. Zinc finger X-chromosomal protein (ZFX) is a significant prognostic indicator and promotes cellular malignant potential in gallbladder cancer. Cancer Biol Ther. 2015;16:1462-1470.

24. Rossi A, Riccio A, Coccia M, Trotta E, Sancho MG. The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. J Biol Chem. 2014;289:12705-12715.

25. Droll D, Minia I, Fadda A, et al. Post-transcriptional regulation of the trypanosome heat shock protein by a zinc finger protein. PLoS Pathog. 2013;9:e1003286.

26. Mia O, Eckhardt BL, Cao Y, et al. Inhibition of established microtumorigenesis by targeted drug delivery via cell surface-associated GRP78. Clin Cancer Res. 2013;19:2107-2116.

27. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Psaltopoulou T. Hsp90 inhibitors in breast cancer: a systematic review. Breast. 2013;22:569-578.
45. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 2003;425:407-410.
46. Nami B, Ghasemi-Dizgah A, Vaseghi A. Overexpression of molecular chaperons GRP78 and GRP94 in CD44(hi)/CD24(lo) breast cancer stem cells. Bioimpacts. 2016;6:105-110.
47. Kurimoto K, Yamaji M, Seki Y, Saitou M. Specification of the germ cell lineage in mice: a process orchestrated by the PR-domain proteins, Blimp1 and Prdm14. Cell Cycle. 2008;7:3514-3518.
48. Nakaki F, Hayashi K, Ohta H, Kurimoto K, Yabuta Y, Saitou M. Induction of mouse germ-cell fate by transcription factors in vitro. Nature. 2013;501:222-226.
49. Nagamatsu G, Kosaka T, Kawasumi M, et al. A germ cell-specific gene, Prmt5, works in somatic cell reprogramming. J Biol Chem. 2011;286:10641-10648.
50. Yamaki H, Nakajima M, Shimotohno KW, Tanaka N. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy. J Antibiot (Tokyo). 2011;64:635-644.
51. Nagaraju GP, Wu C, Merchant N, Chen Z, Lesinski GB, El-Rayes BF. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer. Cancer Lett. 2017;402:110-116.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Moriya C, Taniguchi H, Nagatoishi S, Igarashi H, Tsumoto K, Imai K. PRDM14 directly interacts with heat shock proteins HSP90α and glucose-regulated protein 78. Cancer Sci. 2018;109:373–383. https://doi.org/10.1111/cas.13458